NEW YORK, July 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Dermatology Market Outlook to 2016
http://www.reportlinker.com/p0574966/The-Dermatology-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine
Introduction
This report covers the global dermatology market. The key dermatological indications are profiled in the report and the epidemiology of each of these indications is analysed and forecast to 2016. Leading products in each indication are identified, including those in the pipeline and their sales forecast to 2016. The leading players are profiled and their dermatology revenues forecast to 2016.
Features and benefits
* Analyse the epidemiology of key dermatological indications including acne, psoriasis, dermatitis, rosacea, and skin infections with forecasts to 2016.
* Understand the makeup of the dermatology market in terms of revenues by disease area and individual drugs.
* Forecast the future of the dermatology market with this report's forecasts of sales and epidemiology.
* Understand the future of leading players including Galderma, GSK, Nycomed US, Astellas, and Leo Pharma.
* Analyze the dermatology product pipeline and assess which products have the greatest market potential.
Highlights
Although psoriasis has the smallest patient population of the dermatological indications studied in the report (18 million globally) it has the fastest growing sales and represents almost a fifth of the market. This is indicative of the relative seriousness of the condition and high treatment rates.
Combination products are expected to drive the growth of the anti-acne market segment. The most successful combination products in this market segment are Duac by GSK/Stiefel, BenzaClin by Sanofi, and Ziana by Medicis.
Leo Pharma had dermatology sales of $1.3bn in 2010 which was a near 20% increase on 2009. This increase was largely a result of the reacquisition of the US rights to its products from Watson. Future growth for the company is expected be driven by its pipeline actinic keratosis treatment ingenol mebutate.
Your key questions answered
* Which of the disease areas in the dermatology market have the greatest patient potential through to 2016?
* How big is the dermatology market and which dermatological conditions are the largest opportunities in terms of sales?
* What are the key innovative products that will drive growth in the dermatology market?
* How will the introduction of innovative products impact incumbent products and players?
* What are the strategies of the leading players in this market and how are they forecast to perform through to 2016?
Executive Summary
Overview and epidemiology of dermatological disorders
Global market analysis
Pipeline analysis
Competitive landscape
About Business Insights
Disclaimer
Scope and methodology
Scope
Methodology
Overview and epidemiology of dermatological disorders
Summary
Introduction
Acne
Epidemiology
Forecast epidemiology
Psoriasis
Epidemiology
Forecast epidemiology
Dermatitis
Epidemiology
Forecast epidemiology
Rosacea
Epidemiology
Forecast epidemiology
Infectious diseases of the skin
Viral infections of the skin
Bacterial infections of the skin
Fungal infections of the skin
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Introduction
Market analysis by country
Market analysis by drug class
Leading brand dynamics
Revenue forecasts for the dermatology market
Key events in the dermatology market
Combination products to dominate sales of anti-acne drugs
Stunted growth for biologics in psoriasis treatment
Acne treatments
Key brands analysis
Revenue forecasts for anti-acne drugs
Psoriasis treatment
Key brands analysis
Revenue forecasts for psoriasis drugs
Corticosteroids
Key brands analysis
Revenue forecasts for corticosteroids
Anti-infectives
Key brands analysis
Revenue forecasts
Other brands
Key brands analysis
Revenue forecasts
Pipeline analysis
Summary
Introduction
Pipeline by stage and indication
Key pipeline products
Teplizumab
Ingenol mebutate
Mapracorat
Apremilast
Voclosporin
Tasocitinib
AN2690
Tazarotene foam
Actikerall
Briakinumab
LAS 41002
Competitive landscape
Summary
Introduction
Market share analysis
Detailed analysis of leading players in the dermatology market
GlaxoSmithKline (GSK)
Galderma
Leo Pharma
Nycomed US
Astellas
Revenue forecasts by company
Appendix
Methodology
Glossary/Abbreviations
Bibliography/References
To order this report:
General Medicine and Specialty Medicine Industry: The Dermatology Market Outlook to 2016
General Medicine and Specialty Medicine Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article